Nkoua Epala B¹*, Bintsené Mpika G², Mbongo A², Bolenga Liboko AF⁴, Ndounga E⁴, Moyikoua R³, Ngatali SF⁴and Nsondé Malanda J⁴

¹Radiotherapy Service, CHU Brazzaville, Republic of the Congo
²Gynecology-Obstetrics Department, CHU Brazzaville, Republic of the Congo
³Radiology Department, CHU Brazzaville, Republic of the Congo
⁴Medical Oncology Department, CHU Brazzaville, Republic of the Congo

*Corresponding Author: Nkoua Epala B, Radiotherapy Service, CHU Brazzaville, Republic of the Congo.

Received: May 13, 2021; Published: June 05, 2021

Abstract

Breast cancer is the most common female cancer. Among the therapeutic arsenal in the management of breast cancer, radiotherapy occupies a prominent place. Its indication is systematic toa conservative surgery of an invasive breast cancer or a carcinome in situ breast. However, after radical mastectomy-type surgery, radiation therapy depends on certain factors of poor prognosis. After the treatment of breast cancers with radiotherapy, monitoring is an important stage in life after irradiation because it can either detect and treat the late effects of irradiation, detect and treat a possible tumor recurrence early, or reassure patients of the possibility of complete remission or cure. Post-radiotherapy monitoring is clinical, biological and radiological.

It was a good opportunity for us to take stock of the surveillance of patients with radiotherapy at the University Hospital Centre (CHU) in Brazzaville and abroad for breast cancer.

Keywords: Surveillance; Radiation Therapy; Cancer; Breast; Treatment

References

1. French Society of Oncology Radiotherapy. “Guides external radiotherapy procedures 2007”. Radiotherapy Cancer 12 (2008): 141-314.
2. Burstein HJ and Winer EP. “Primary care for survivors of breast cancer”. The New England Journal of Medicine 343 (2000): 1086-1094.
3. De Bock GH., et al. “Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: A meta-analysis and systematic review”. Journal of Clinical Oncology 22 (2004): 4010-4018.
4. Goss PE., et al. “A randomized trial of letrozol in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer”. The New England Journal of Medicine 349 (2003): 1793-1802.
5. Coombs RC., et al. “A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer”. The New England Journal of Medicine 350 (2004): 1081-1092.
6. The ATAC Trialists’ Group. “Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial”. Lancet 359 (2002): 2131-2139.
7. Smith IE., et al. “Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea : Caution and suggested guidelines”. Journal of Clinical Oncology 24 (2006): 2444-2447.
8. Hilner BE., et al. “American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer”. Journal of Clinical Oncology 21 (2003): 4042-4047.
9. Perez EA and Rodeheffer R. “Clinical cardiac tolerability of trastuzumab”. Journal of Clinical Oncology 22 (2004): 322-329.
10. Praga C., et al. “Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer : Correlation with doses of epirubicin and cyclophosphamide”. Journal of Clinical Oncology 23 (2005): 4179-4191.
11. Grunfeld E., et al. “Randomized trial of long-term follow-up for early-stage breast cancer: A comparison of family physician versus specialist care”. Journal of Clinical Oncology 24 (2006): 848-855.
12. Goldhirsch A., et al. “Progress and promise : Highlights of the international expert consensus on the primary therapy of early breast cancer 2007”. Annals of Oncology 18 (2007): 1133-1144.
13. Hennequin AP., et al. “Radiation of lymph node areas in breast cancer”. Cancer/Radiotherapie 12 (2008): 559-564.
14. Smith I-E and Ross G-M. “Breast radiotherapy after no longer always necessary”. The New England Journal of Medicine 351 (2004): 1021-1023.
15. Sindy M and Vlastos G. “Management of axillary hollow in breast cancer”. Imagery of Women 7 (2009): 100-104.
16. Belaida A., et al. “Breast cancer with axillary lymph node disease”. Cancer/Radiotherapie 1 (2010): 136-146.
17. Evans PM., et al. “The delivery of intensity modulated radiotherapy to the breast using multiple staticfields”. Radiotherapy Oncology 57 (2000): 79-89.
18. Class J., et al. “Invasive Breast Cancer Surgery”. Journal of Obstetrics and Reproductive Biology 395 (2010): 43-62.
19. Tournemaine T., et al. “Diagnostic Strategy in Surveillance of Treated Breasts” 11.1-2 (2001): 10.
20. Treilleux I and Bremond A. “Breast Cancer Prognosis”. Encycl Med Chir. (Elsevier, bets), Gynecology 7 (2002): 100.
21. Cutuli B. “Radiation and breast cancer, news and development”. 13.3 (2003): 277-282.
22. Namer M., et al. “Breast Cancers: Recommendations for the Clinical Practice of St. Paul-de – Vence”. Oncology 7 (2005): 345-352.

Citation

Citation: Nkoua Epala B., et al. “Monitoring of Patients Treated with Radiation Therapy for Breast Cancer”. Acta Scientific Cancer Biology 5.7 (2021): 19-24.

Copyright

Copyright: © 2021 Nkoua Epala B., et al.. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.